A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 421-424

  Oishi, Tetsuro ^a   Kigawa, Junzo ^a   Fujiwara, Keiichi ^b   Fujiwara, Michihisa ^c   Numa, Fumitaka ^d   Aotani, Eriko ^e   Katsumata, Noriyuki ^f   Kohno, Ichiro ^b   Kato, Hiroshi ^d   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Kawasaki Hospital   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

^f NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EVALUATION; FEMALE; HUMAN; MYALGIA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0043125628     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00322-6     Document Type: Article

References (17)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Pearson C.D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
2. Neijt J.P., Engelholm S.A., Witteveen P.O., Tuxen M.K., Sorensen P.G., Hansen M., Hirsch F., Sessa C., de Swart C., van Houwelingen H.C., Lund B., Hansen S.W. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer an interim analysis . Semin Oncol. 24:1997;36-39.
3. Muggia F.M. Cisplatin update. Semin Oncol. 18:1991;1-4.
4. Kigawa J., Minagawa Y., Ishihara H., Kanamori Y., Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer. 72:1993;804-808.
5. Hortobagyi G.N. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol. 26:(Suppl):1999;32-36.
6. Engblom P., Rantanen V., Kulmala J., Heiskanen J., Grenman S. Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res. 17:1997;2475-2479.
7. Piccart M.J., Gore M., Ten Bokkel Huinink W., van Oosterom A., Verweij J., Wanders J., Franklin H., Bayssas M., Kaye S. Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer . J Natl Cancer Inst. 87:1995;676-681.
8. Verschraegen C.F., Sittisomwong T., Kudelka A.P., Guedes E.D., Steger M., Nelson-Taylor T., Vincent M., Rogers R., Atkinson E.N., Kavanagh J.J. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 18:2000;2733-2739.
9. Kaye S.B., Piccart M., Aapro M., Francis P., Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer. 33:1997;2167-2170.
10. Benjapibal M., Kudelka A.P., Vasuratna A., Edwards C.L., Verschraegen C.F., Valero V., Vadhan-Raj S., Kavanagh J.J. Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs. 9:1988;577-579.
11. Anderson H, Boman K, Ridderheim M, Rosenberg P, Sorbe B, Puistola U, Horvath G. An updated analysis of a randomized study of single agent paclitaxel given weekly vs. every 3 weeks to patients with ovarian cancer. ASCO Proc 2000; 1505.
12. Greco F.A. Docetaxel administered in weekly schedules. Semin Oncol. 26:(Suppl 11):1999;28-31.
13. Shin E., Ishitobi M., Hirooka M., Kazumasa F. Phase I study of docetaxel administered by biweekly infusion to patients with metastatic breast cancer. Anticancer Res. 20:2000;4721-4726.
14. Fujiwara K., Kohno I., Tanaka K., Ogita S., Sasaki Y., Hirabayashi K., Yakushiji M., Tsunematsu R., Terashima Y., Taguchi T., Ohashi Y., Noda K. Phase II dose escalation a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group . Anticancer Res. 19:1999;639-644.
15. Noda K., Terajima Y., Ogita Y., Kohno I., Hirabayashi K., Yakushiji M., Taguchi T. Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri. Jpn J Cancer Chemother. 21:1994;2471-2477.
16. Michaud L.B., Valero V., Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 23:2000;401-428.
17. Katsumata N., Tsunematsu R., Tanaka K., Terashima Y., Ogita S., Hoshiai H., Kohno I., Hirabayashi K., Yakushiji M., Noda K., Taguchi T. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer a Japanese cooperative study . Ann Oncol. 11:2000;1531-1536.